表柔比星及环磷酰胺联合白蛋白紫杉醇在乳腺癌新辅助化疗中的应用效果与安全性观察

Application effect and safety of epirubicin and cyclophosphamide combined with albumin paclitaxel in neoadjuvant chemotherapy for breast cancer

目的:探讨表柔比星+环磷酰胺联合白蛋白紫杉醇在乳腺癌(BC)新辅助化疗中的应用效果与安全性。方法:回顾性分析2016年6月—2019年9月就诊的111例BC患者的临床资料,依据化疗方案的不同分为TEC组(58例)和PEC组(53例),其中TEC组给予表柔比星、环磷酰胺联合多西他赛化疗,PEC组给予表柔比星、环磷酰胺联合白蛋白紫杉醇化疗。比较两组患者的近期治疗效果及不良反应发生率。结果:PEC组总有效率为79.25%,高于TEC组的62.07%,差异有统计学意义(P<0.05);PEC组和TEC组不良反应发生率分别为15.09%和22.41%,两组比较差异无统计学意义(P>0.05)。结论:表柔比星和环磷酰胺联合白蛋白紫杉醇在BC新辅助化疗中的应用效果显著,不良反应可耐受。

Objective:To explore application effect and safety of epirubicin and cyclophosphamide combined with albumin paclitaxel in neoadjuvant chemotherapy for breast cancer(BC).Methods:The clinical data of 111 BC patients who were treated in the hospital from June 2016 to September 2019 were retrospectively selected.According to different chemotherapy regimens,they were divided into TEC group(58 cases)and PEC group(53 cases).TEC group was given epirubicin,cyclophosphamide and docetaxel for chemotherapy,while PEC group was given epirubicin,cyclophosphamide and albumin paclitaxel for chemotherapy.The short-term curative effect and total incidence of adverse reactions were compared between the two groups.Results:The total response rate of treatment in PEC group was higher than that in TEC group(79.25%vs 62.07%)(P<0.05).The total incidence of adverse reactions in PEC group and TEC group was 15.09%and 22.41%,respectively(P>0.05).Conclusion:The curative effect of epirubicin and cyclophosphamide combined with albumin paclitaxel is significant in BC neoadjuvant chemotherapy.And adverse reactions can be tolerated.